Astria Therapeutics (NASDAQ:ATXS) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Astria Therapeutics (NASDAQ:ATXS) issued its earnings results on Tuesday. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01, Zacks reports.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock traded down $0.02 during trading hours on Tuesday, reaching $5.80. The company’s stock had a trading volume of 31,372 shares, compared to its average volume of 258,779. The company has a market capitalization of $327.20 million, a P/E ratio of -2.77 and a beta of 0.69. The stock’s fifty day simple moving average is $7.32 and its two-hundred day simple moving average is $9.65. Astria Therapeutics has a one year low of $5.75 and a one year high of $16.90.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ATXS. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Thursday, February 27th. Oppenheimer upped their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Finally, JMP Securities started coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $25.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.